ISELIN, N.J., July 1, 2015 /PRNewswire/ -- Echo
Therapeutics, Inc. (NASDAQ: ECTE), a medical device company focused
on non-invasive continuous glucose monitoring and associated
technologies, today announced the launch of its new and completely
re-designed corporate website echotx.com. Echo's new site provides
quick and intuitive access to Echo's technology and enhances the
quality and availability of company information.
The new website better communicates to prospective customers and
stakeholders what Echo can bring to market – a leading edge,
non-invasive continuous glucose monitoring technology for the
diabetes and wearable health markets.
"Our new website reflects the direction we are heading and
reinforces our dedication to providing the best user-experience. By
shifting the focus to the benefits that people can gain with our
product, we are showing how our continuous glucose sensing
technology can fit into everyone's daily lives," commented
Scott Hollander, Echo's President
and CEO. "As we move toward the anticipated commercialization
of our technology, we are eager to communicate directly with the
public to share valuable information in a timely manner."
About Echo Therapeutics
Echo Therapeutics is developing its non-invasive, wireless,
continuous glucose monitoring (CGM) system. A significant
opportunity exists for the Company's CGM to be used in the fitness,
weight loss and personal lifestyle wearable-health space. A
longer-term opportunity also exists in the outpatient diabetes and
hospital settings. Echo developed its needle-free skin preparation
device as a platform technology that allows for enhanced skin
permeation enabling extraction of analytes, such as glucose, and
enhanced delivery of topical pharmaceuticals.
Cautionary Statement Regarding Forward Looking
Statements
The statements in this press release that are not historical
facts may constitute forward-looking statements that are based on
current expectations and are subject to risks and uncertainties
that could cause actual future results to differ materially from
those expressed or implied by such statements. Those risks and
uncertainties include, but are not limited to, risks related to
regulatory approvals and the success of Echo's clinical studies,
the safety and efficacy of Echo's CGM System, the failure of future
development and preliminary marketing efforts related to Echo's CGM
System, Echo's ability to secure additional commercial partnering
arrangements, risks and uncertainties relating to Echo's and its
partners' ability to develop, market and sell Echo's CGM System,
the availability of substantial additional equity or debt capital
to support its research, development and product commercialization
activities, and the success of its research, development,
regulatory approval, marketing and distribution plans and
strategies, including those plans and strategies related to its CGM
System. These and other risks and uncertainties are identified and
described in more detail in Echo's filings with the Securities and
Exchange Commission, including, without limitation, its Annual
Report on Form 10-K for the year ended December 31, 2014, its Quarterly Reports on Form
10-Q, and its Current Reports on Form 8-K. Echo undertakes no
obligation to publicly update or revise any forward-looking
statements.
For More Information:
Christine H.
Olimpio
Director, Investor Relations and Corporate Communications
(732)
549-0128
Connect With Us:
- Visit our new website at
www.echotx.com
- Follow us on Twitter at www.twitter.com/echotx
- Join us on Facebook at www.facebook.com/echotx
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/echo-therapeutics-announces-new-website-launch-300107402.html
SOURCE Echo Therapeutics, Inc.